Daniel S. Goldman sold Fate Therapeutics Inc (NASDAQ: FATE)
Daniel S. Goldman (D-NY), a U.S. Representative, has disclosed 1 trade in Fate Therapeutics Inc (FATE) since 2023, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Daniel S. Goldman sold $1,001 - $15,000 of Fate Therapeutics Inc (NASDAQ: FATE) on January 31, 2023. Since that trade, FATE is down -57.89% against the S&P 500 up +90.34%, an outperformance of -148.23%.
Data updated
Daniel S. Goldman's FATE trades vs the price
FATE is down -57.89% since Daniel S. Goldman sold on January 31, 2023, versus +90.34% for the S&P 500.
Performance since this trade
All Daniel S. Goldman FATE trades
Daniel S. Goldman & FATE trading FAQ
Is it legal for Daniel S. Goldman to trade Fate Therapeutics Inc (FATE) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Fate Therapeutics Inc (FATE), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Daniel S. Goldman sell FATE?
Daniel S. Goldman disclosed a sale of $1,001 - $15,000 of Fate Therapeutics Inc (FATE) on January 31, 2023, according to public STOCK Act filings.
How has FATE performed since Daniel S. Goldman's trade?
Since Daniel S. Goldman sold FATE on January 31, 2023, the stock is down -57.89%, versus +90.34% for the S&P 500 over the same period, an outperformance of -148.23%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional FATE trades?
Quantellect tracks every disclosed congressional trade in Fate Therapeutics Inc (FATE) on the Fate Therapeutics Inc congressional trading page, which aggregates filings across all members of Congress.
Daniel S. Goldman's FATE tradesAll congressional filings for Fate Therapeutics IncDaniel S. Goldman's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.